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Abstract
Poly(ethylene glycol) (PEG) conjugated lipids have been used to increase the circulation longevity of liposomal carriers
encapsulating therapeutic compounds. PEG is typically conjugated to distearoylphosphatidylethanolamine (DSPE) via a
carbamate linkage that results in a net negative charge on the phosphate moiety at physiological pH. It was anticipated that the
presence of this negative charge could have deleterious effects on liposome pharmacokinetic characteristics. We describe here
the synthesis of a new class of neutrally charged PEG-lipid conjugates in which the PEG moiety was linked to ceramide
(CER). These PEG-CER conjugates were compared with PEG-DSPE conjugates for their effects on the pharmacokinetics of
liposomal vincristine. PEG-CER (78% palmitic acid, C16) and PEG-DSPE achieved comparable increases in the circulation
lifetimes of sphingomyelin/cholesterol (SM/chol) liposomes. However, PEG-DSPE significantly increased the in vitro and in
vivo leakage rates of vincristine from SM/chol-based liposomes compared to vincristine leakage observed when PEG-CER
was used. The increase in drug leakage observed in vitro that was due to the presence of PEG-DSPE was likely due to the
presence of a negative surface charge. Analysis of the electrophoretic mobilities of these formulations suggested that the
negative surface charges were shielded by approx. 80% by the PEG layer extending from the membrane surface. In contrast,
formulations containing PEG-CER had no surface charge and no electrophoretic mobility. A comparison of the effects of the
ceramide acyl chain length (C8 through C24) on the pharmacokinetics of SM/chol/PEG-CER formulations of vincristine
demonstrated that longer acyl chains on the PEG-CER were associated with longer circulation lifetimes of the liposomal
carriers and, consequently, higher plasma vincristine concentrations. These data suggest that the short chain PEG-ceramides
underwent rapid partitioning from the vesicles after i.v. administration, whereas the longer chain PEG-ceramides had stronger
anchoring properties in the liposome bilayers and partitioned slowly from the administered vesicles. These data demonstrate
the utility of ceramide-based steric stabilizing lipids as well as the potential for developing controlled release formulations by
manipulating the retention of the PEG-ceramide conjugate in liposome bilayers. ß 1998 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Liposomes have been extensively characterized as
delivery vehicles that e¡ectively prolong the circula-
tion longevity of a wide variety of therapeutic agents
after parenteral administration, reduce drug toxicity
and increase drug accumulation at disease sites. It is
widely accepted for many therapeutic agents that in-
creases in the drug’s circulation longevity is associ-
ated with increased therapeutic activity. To this end,
modi¢cations to liposomal carriers that increase their
circulation lifetime have been reported to cause sub-
stantial increases in the therapeutic activity of the
drug [1,2]. Typically, these modi¢cations have been
achieved by incorporating poly(ethylene glycol)
(PEG) that has been conjugated to phosphatidyletha-
nolamine (PE) in the liposomal membrane [3]. While
a variety of di¡erent PEG sizes may be conjugated to
the phospholipid, and conjugation may be achieved
with many distinct chemical linkages [4], the com-
mon feature of these approaches is the use of PE
(typically distearyol-PE, DSPE) as the lipid anchor.
Further, most commercially available PEG-PE is
synthesized with a carbamate linkage that results in
a net negative charge on the phosphate headgroup of
the conjugate at physiological pH [5].
We anticipated that the incorporation of a non-
charged PEG-lipid yielding a neutral surface electro-
static charge would increase the circulation lifetimes
of liposomes beyond that achieved using PEG-PE.
Negative liposome surface charge has been closely
associated with rapid clearance from the circulation
[6] and both negative surface potentials and electro-
phoretic mobility are present in liposomes containing
PEG-PE [5]. It was also anticipated that a reduction
in the negative surface charge of the liposomes in the
presence of PEG-lipids might reduce the leakage
rates of encapsulated cationic drugs since the neutral
bilayer surface will not attract positively charged
drug to the membrane surface. To achieve these
characteristics, we have chosen to conjugate PEG
to ceramides using linkage chemistry that results in
a neutral, non-charged molecule at physiological pH.
Given the increased drug leakage observed for
sphingomyelin/cholesterol formulations of vincristine
when PEG-DSPE was incorporated as a steric-stabi-
lizing lipid [7], we utilized liposomal vincristine as a
model system to evaluate the e¡ect of membrane
surface charge on drug retention. In this report, we
compare PEG-DSPE and PEG-CER containing lip-
osomes for their in vivo pharmacokinetics and drug
retention characteristics. In addition, we examine the
in£uence of the hydrophobic anchor on circulation
longevity and drug retention for neutral PEG-ceram-
ides having a variety of acyl chain lengths.
2. Materials and methods
2.1. Materials
Egg sphingomyelin (SM) and D-sphingosine were
purchased from Avanti Polar Lipids and used with-
out further puri¢cation. Cholesterol (chol) was ob-
tained from Sigma (St. Louis, MO, USA) and poly-
(ethylene glycol)2000-distearoylphosphatidylethanol-
amine (PEG-DSPE) from Northern Lipids (Vancou-
ver, B.C., Canada). Vincristine sulfate (Oncovin) was
obtained from Eli Lilly (Canada). Cholesteryl-4-hex-
adecyl ether (CHDE) radiolabeled with 14C was ob-
tained from New England Nuclear. [3H]Vincristine
was obtained from Amersham (Canada). All other
chemicals were obtained from Sigma (St. Louis,
MO, USA). Female BDF1 mice (8^10 weeks old)
were obtained from Charles River Laboratories.
2.2. Synthesis of MePEG2000-S
Monomethoxypolyethylene glycol (average
MW = 2000; MePEG2000) (4 g) was dissolved in
30 ml of CH2Cl2 and treated with 600 mg of succinic
anhydride, 400 mg triethylamine and 250 mg 4-di-
methylaminopyridine (DMAP) by stirring under ni-
trogen gas for 16 h at 20‡C. The reaction solution
was diluted with 60 ml of CH2Cl2 and then cooled
on ice and 50 ml of water was added. This mixture
was acidi¢ed with 1 N HCl and the organic layer
recovered. The aqueous layer was further extracted
twice with 30 ml of CH2Cl2 and the combined or-
ganic extracts were dried. The crude product was
puri¢ed on silica gel (G60) column eluted with
CH2Cl2 containing 2^8% methanol. Column frac-
tions were analyzed by thin layer chromatogra-
phy (TLC) (silica gel, CHCl3/CH3OH 88:12, v/v)
and fractions containing the pure product of
MePEG2000-S (Rf = 0.4) were pooled and concen-
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trated. Trituration with diethyl ether yielded 3.2 g of
white MePEG2000-S product.
2.3. Synthesis of C8-, C14- and C20-ceramides
N-Hydroxysuccinimide (NHS) esters of octanoic
acid, myristic acid, eicosanoic acid and tetracosanoic
acid were synthesized as described previously [8].
One mmole of each ester was added to a solution
of 300 mg of D-sphingosine in 16 ml of anhydrous
CH2Cl2 and containing 118 mg of triethylamine. The
mixture was stirred under nitrogen gas for 4 h at 20^
30‡C. Analysis by TLC (silica gel, CHCl3/CH3OH/
H20 65:25:4 v/v/v or CHCl3/CH3OH 9:1 v/v) indi-
cated that most of the D-sphingosine had reacted.
The reaction mixture was cooled on ice and diluted
with 60 ml of CH2Cl2, 30 ml of H2O and then neu-
tralized with 1 N HCl. The CH2Cl2 layer was washed
twice with 30 ml of H2O and then dried in vacuo.
The residue was recrystalized twice from acetone to
yield the pure product.
2.4. Synthesis of MePEG2000-S-ceramides
The egg ceramide used here was obtained from
Avanti Polar Lipids and derived from egg sphingo-
myelin. This egg ceramide had the amide composi-
tion of egg sphingomyelin and was comprised pre-
dominantly of palmitic acid (78 mol% of 16:0 and
7 mol% of 18:0, with the remainder comprised of
2^4 mol% of 20:0, 22:0, 24:0 and 24:1) and will be
referred to as PEG-CER (C16) here. The appropriate
ceramide (egg ceramide or speci¢c fatty acyl ceram-
ides synthesized as above) were mixed with dicyclo-
hexylcarbodiimide (DCC) and DMAP in 6^8 ml of
warm anhydrous CH2Cl2 in weight ratios of ceram-
ide/DCC/DMAP approx. 4.5:2:1. MePEG2000-S in
2 ml of anhydrous CH2Cl2 was added dropwise to
the above solution, at a MePEG2000-S/ceramide
weight ratio of approx. 4:1, and stirred under nitro-
gen gas for 6 h at room temperature. Any precipi-
tated dicyclohexylurea was ¢ltered o¡ and the ¢ltrate
was concentrated in vacuo. Trituration of the solid
residue with diethyl ether removed most of the DCC,
DMAP and unreacted ceramide. The crude product
was chromatographed on a short silica gel column
(G60) eluted with CH2Cl2/CH3OH (92:2, v/v) and
the fractions containing the product were combined,
evaporated to dryness then dissolved in distilled
water and dialyzed at 4‡C overnight against distilled
water. Lyophilization of the product yielded a white
powder which was detected as a single spot after
TLC analysis (Rf = 0.5 on silica gel in CHCl3/CH3OH
9:1, v/v).
2.5. 1H-Nuclear magnetic resonance
The initial ceramide, initial MePEG2000-S and the
¢nal PEG-ceramide products were dissolved in
CDCl3 and analyzed by 1H-nuclear magnetic reso-
nance (1H-NMR) using a Bruker 400 MHz instru-
ment using residual chloroform (NH 7.24) as the
reference.
2.6. Liposome preparation and vincristine loading
The preparation of liposomes and their loading
with vincristine has been described in detail previ-
ously [7]. Brie£y, lipid ¢lms containing 2^5 WCi
[14C]CHDE were prepared by the drying of lipid sol-
utions in chloroform/methanol under high vacuum.
These lipid ¢lms were hydrated at 100 mg lipid/ml in
0.3 M citrate (pH 4.0) to produce multilamellar
vesicles. Large unilamellar vesicles were obtained
by repeated extrusion of the hydrated lipids through
two stacked 0.1 Wm ¢lters (Poretics, Livermore, CA,
USA) held at 60^65‡C in a Thermobarrel extruder
(Lipex Biomembranes, Vancouver, Canada). Lipo-
some mean diameters, con¢rmed by quasi-elastic
light scattering using a Nicomp 270 or Nicomp
T370 particle sizer, were typically 120^130 nm. The
uptake of vincristine into these vesicles was accom-
plished in response to a transmembrane pH gradient
[9]. A solution of vincristine, containing [3H]-
vincristine, was added to the liposomes to
achieve a ¢nal drug/lipid ratio of 0.1:1 (w/w). A
transmembrane pH gradient was generated by
the addition of su⁄cient 0.5 M disodium hydrogen
phosphate to bring the external pH to 7.2^7.6. Vin-
cristine uptake was allowed to proceed for 10 min at
60‡C. Uptake e⁄ciencies were checked by chroma-
tography of aliquots of the loaded liposomes on a
Sephadex G-50 column and were typically greater
than 95%.
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2.7. In vitro release of vincristine from liposomes
Liposomal vincristine was prepared as described
above. After vincristine loading, the preparations
were diluted 1:1 with mouse serum (Sigma) then
transferred into a dialysis tubing (Spectra/Por, mo-
lecular weight cuto¡ = 3500). Samples were dialyzed
against 1500 vols. of 150 mM NaCl, 20 mM HEPES
(pH 7.5) at 37‡C for up to 72 h. At various times,
aliquots were taken from the dialysis tubing then
passed over a Sephadex G-50 column. Eluates were
analyzed by liquid scintillation counting (LSC) for
quantitation of lipid and drug.
2.8. Electrophoretic mobility measurements
Lipid mixtures were prepared in chloroform/meth-
anol as described above, but without [14C]CHDE,
then rehydrated in 10 mM sodium chloride (pH
7.0). Each dispersion of multilamellar vesicles was
placed in a cylindrical microelectrophoresis chamber
(Rank Mark I) and an electric ¢eld of 3.9 V/cm was
applied at a temperature of 25‡C. Vesicle migration
in the electric ¢eld was determined by timing vesicle
passage through a pre-determined number of squares
that were viewed at a magni¢cation of 40U. The
largest in-focus particles were examined and no size
dependence was observed. Each preparation was
measured 20 times, accomplished by ten measure-
ments in each direction with the polarities switched
between timings. The electrophoretic mobility was
calculated from the averaged velocities, the applied
voltage and the chamber electrical length. Fixed red
blood cells had a mobility of 31.2 ( þ 0.1) cm2/Vs in
0.10 M NaCl.
2.9. Pharmacokinetics of liposomal vincristine
formulations
Liposomal formulations of vincristine prepared as
described above using [3H]vincristine and
[14C]CHDE as a lipid label. The formulations were
diluted to the appropriate concentrations for admin-
istration using 150 mM NaCl, 20 mM HEPES
(pH 7.5) and administered to female mice by lateral
tail vein injection at a vincristine dose of 2.0 mg/kg
(corresponding to a lipid dose of 20 mg/kg). At var-
ious times after liposome administration, blood was
recovered by cardiac puncture from three animals
per treatment group. Lipid and vincristine quantities
in the plasma were assayed by LSC.
3. Results
3.1. Characterization of PEG-ceramides
The chemical structure of the PEG-ceramides is
shown in Fig. 1. All synthetic products were analyzed
by TLC and gave single spots at the expected Rf
values for the pure products. In addition, the ¢nal
products were analyzed by 1H-nuclear magnetic res-
Fig. 1. Chemical structures of PEG-DSPE and PEG-ceramides.
The structure for PEG2000-DSPE is modi¢ed from that provided
by Avanti Polar Lipids and it is assumed that 45 poly(ethylene
glycol) groups are used to comprise a 2000 Da PEG moiety.
For the PEG-ceramides, the R group was C7H15 (for the C8-
ceramide), C13H27 (for the C14-ceramide), C15H31 (78 mol%;
for the egg ceramide), C19H39 (for the C20-ceramide) or C23H47
(for the C24-ceramide).
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onance to con¢rm that the products had the expected
structure. Data for PEG-ceramide (C8) are presented
in Fig. 2 by way of example. The complete character-
ization of the PEG-ceramides is to be presented in a
separate paper (Wang et al., manuscript in prepara-
tion).
For PEG-ceramide (C8), the methyl and methylene
proton resonances between 0.8 and 2.5 ppm clearly
arose from the ceramide (C8) starting material (com-
pare Fig. 2C with A). Similarly, resonances between
5.5 and 6.5 ppm in the PEG-ceramide material
(Fig. 2C) were also derived from the ceramide (C8)
starting material (Fig. 2A). The complex of resonan-
ces in the range of 3.0^4.0 ppm arose from the PEG
polymer protons (Fig. 2B). The speci¢city of the con-
jugation to the hydroxyl of the primary carbon of the
ceramide is shown by the down¢eld shift of the
methylene protons from 3.92 ppm in the starting
ceramide (Fig. 2A) to 4.12 ppm in the ¢nal PEG-
ceramide product (Fig. 2C). This shift was due to
the primary ester linkage of the PEG moiety. In con-
trast, the proton on the tertiary carbon, and adjacent
to the second hydroxyl group to which PEG might
conjugate, had a resonance at 4.3 ppm in the starting
ceramide (C8) (Fig. 2A) that remained at 4.3 ppm in
the PEG-ceramide (C8) product (Fig. 2C). Since the
down¢eld shift of this proton was not a¡ected by
PEGylation of the ceramide, these data indicate
that the conditions used for the coupling of
PEG2000-S with ceramide yielded predominantly the
MePEG2000-S-ceramide product attached via the pri-
mary ester linkage.
3.2. In vitro characterization of liposomal
formulations containing PEG-CER or
PEG-DSPE
A variety of liposomal formulations of vincristine
were evaluated for drug loading and subsequent drug
retention during dialysis in the presence of mouse
serum. Encapsulated vincristine was very well re-
tained in SM/chol liposomes, with a half-life for
drug release of 219 h (Table 1). The addition of the
anionic lipid PEG-DSPE to SM/chol liposomes de-
creased the retention half-life of vincristine from
219 h to 101 h, an increase in leakage rate of 117%
(Table 1). In contrast, identical proportions of the
neutral PEG-CER induced only a 40% increase in
drug leakage rate (Table 1). Since the PEG-DSPE
molecule has a net negative surface charge, we exam-
ined the e¡ects of naturally occurring anionic phos-
pholipids on the retention of vincristine in SM/chol
liposomes. The addition of 5 mol% of anionic lipids
DSPG or DOPS decreased the half-life of vincristine
retention to 115 h and 62 h, respectively. These de-
creases in half-life represent increases in vincristine
leakage rates of 90% and 253% respectively and are
comparable to that e¡ected by PEG-DSPE.
To better understand the physical characteristics
Fig. 2. 1H-NMR spectra of ceramide (A), MePEG2000-S (B)
and PEG-ceramide (C8) (C).
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of these liposomes that may be contributing to
changes in vincristine retention and/or liposome cir-
culation lifetimes, we examined the electrophoretic
mobilities of several formulations in an electric ¢eld
(Table 1). The neutral SM/chol liposomes and SM/
chol containing 5 mol% of the neutral PEG-CER
had no movement in an applied electric ¢eld
(Table 1). The presence of 5 mol% of either anionic
phospholipid DSPG or DOPS resulted in a substan-
tial negative electrophoretic mobility of approx.
34.2U1034 cm2/Vs (Table 1). The anionic lipid
PEG-DSPE, although carrying a net negative charge
on its headgroup similar to that of DSPG and
DOPS, conferred only a modest negative electropho-
retic mobility of 30.83U1034 cm2/Vs, a value 80%
lower than that observed with an identical molar
proportion of DOPS or DSPG. The electrophoretic
mobility of the SM/chol/PEG-DSPE formulation was
signi¢cantly di¡erent from that of the SM/chol/PEG-
CER formulation.
3.3. Pharmacokinetic comparison of PEG-CER with
PEG-DSPE in liposomal vincristine
The preceding analysis of SM/chol liposomes con-
taining PEG-DSPE or PEG-CER indicated that the
electrophoretic mobilities (or their directly related
zeta potentials) of these two formulations were
slightly, but signi¢cantly, di¡erent (Table 1). Since
a negative surface charge on liposomes is associated
with rapid liposome clearance after administration
[6], the di¡erent electrophoretic mobilities on SM/
chol liposomes containing PEG-DSPE and PEG-
CER suggested that these formulations might also
have di¡erent circulation lifetimes. The addition of
5 mol% of either PEG-DSPE or PEG-CER (C16) to
SM/chol formulations of vincristine increased both
the plasma concentrations and the circulation life-
times of the liposomes (Fig. 3A). As a result, the
plasma lipid concentrations at 24 h after i.v. admin-
istration were comparable, between 153 ( þ 13) and
185 ( þ 8) Wg lipid/ml plasma in the PEG-CER and
PEG-DSPE containing formulations, respectively,
compared to 116 ( þ 9) Wg lipid/ml plasma for SM/
chol (Fig. 3A). In addition, PEG-CER and PEG-
DSPE conferred identical increases in the circulation
lifetimes of conventional DSPC/chol based liposomes
when added at 5 mol% (data not shown).
A negative surface charge on liposomes conferred
by the presence of the anionic lipids DOPS and
DSPG was associated with increased vincristine leak-
age (Table 1). Similar increases in drug leakage were
induced in vitro by the presence of PEG-DSPE
whereas the neutrally charged PEG-CER had only
modest e¡ects on vincristine release from the lipo-
somes (Table 1). However, in vivo the addition of
5 mol% of either PEG-DSPE or PEG-CER (C16)
to SM/chol-based formulations was associated with
signi¢cantly reduced vincristine retention, as shown
by lower vincristine/lipid ratios compared to SM/chol
formulations, at all times between 1 and 24 h after
i.v. administration (Fig. 3B). Calculation of the half-
lives of drug release from these liposomal carriers in
vivo demonstrated that the rate of vincristine leakage
was greater from the SM/chol/PEG-DSPE formula-
tion than either the SM/chol/PEG-CER (C16) or
SM/chol formulations (Fig. 3B). Speci¢cally, the
t1=2 values for drug leakage were 29.1 and 33.0 h
Table 1
Summary of the in vitro characteristics of various liposomal formulations
Formulation (mol/mol) In vitro vincristine leakage Electrophoretic mobility (U1034 cm2/Vs)
t1=2 (h) r2
SM/chol (55:45) 219 0.96 0.0
SM/chol/DSPG (50:45:5) 115 0.99 34.18 ( þ 0.25)
SM/chol/DOPS (50:45:5) 62 0.98 34.24 ( þ 0.31)
SM/chol/PEG-DSPE (50:45:5) 101 0.96 30.83 ( þ 0.05)
SM/chol/PEG-CER (C14) (50:45:5) 156 0.99 0.0
The in vitro vincristine leakage t1=2 values were calculated from 0.693/3k, where k is the slope of the time vs. ln(% drug/lipid ratio)
plot [7] during dialysis in 50% mouse serum. The correlation coe⁄cient (r2) for these plots is also given. Electrophoretic mobilities
were obtained from multilamellar dispersions of the lipid formulations in the absence of encapsulated vincristine as described in Sec-
tion 2.
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for the SM/chol and SM/chol/PEG-CER formula-
tions compared to 23.9 h for SM/chol/PEG-DSPE (r2
values for these regressions of the ln % D/L vs. time
plots were 0.99, 0.88 and 0.85, respectively). This
represents a 22% increase in the vincristine leakage
rate by the addition of PEG-DSPE to SM/chol lip-
osomes. A very similar decrease of the in vivo t1=2 for
vincristine retention from 33.3 h for SM/chol to 26.8
h for SM/chol/PEG-DSPE, representing a 24% in-
crease in drug release rate, has been reported previ-
ously [7]. The alterations in carrier circulation life-
times due to the presence of either PEG-DSPE or
PEG-CER (C16) in SM/chol liposomes (Fig. 3A)
were counteracted by the alterations in vincristine
retention in these carriers such that the overall vin-
cristine levels in the plasma were not a¡ected by the
presence of either PEG-conjugated lipid (Fig. 3C).
The calculated t1=2 values for vincristine lifetime in
the circulation were 9.2, 10.9 and 10.6 h for the SM/
chol, SM/chol/PEG-DSPE and SM/chol/PEG-CER
formulations, respectively.
3.4. E¡ect of PEG-CER acyl chain length on
liposomal vincristine pharmacokinetics
Since PEG-modi¢ed lipids are amphiphiles pos-
sessing large (approx. 2000 Da) hydrophilic moieties
and a hydrophobic carbon chain moiety that acts to
anchor the molecule in the bilayer, it was anticipated
that the propensity of the PEG-conjugated lipids to
partition out of the bilayer could be regulated by
alterations in the balance of hydrophilic and hydro-
phobic domains. In practice, we have e¡ected
changes in the hydrophilic/hydrophobic balance via
modi¢cations to the carbon chain length of the hy-
drophobic anchor. Consequently, we have examined
SM/chol formulations of vincristine containing
5 mol% of PEG-ceramide having di¡erent acyl chain
Fig. 3. Pharmacokinetic analysis of SM/chol (55:45, mol/mol)
(a), SM/chol/PEG-DSPE (50:45:5, mol/mol/mol) (b) and SM/
chol/PEG-CER (C16) (50:45:5) (F) formulations of vincristine.
(A) Concentrations of liposomal lipid in the plasma at various
times after i.v. administration. (B) Vincristine/lipid ratio (% of
the administered vincristine/lipid ratio) in the plasma at various
times after i.v. administration. (C) Concentrations of vincristine
in the plasma at various times after i.v. administration. Data
represent the mean ( þ S.E.) of four animals.
Fig. 4. Comparison of the e¡ect of di¡erent PEG-conjugated
lipids on circulation longevity of SM/chol formulations of vin-
cristine. Data represent the proportions of the injected lipid
dose (20 mg/kg) remaining in the circulation at 24 h after i.v.
administration for SM/chol formulations without a PEG-conju-
gated lipid (no PEG) or containing 5 mol% of either PEG-
DSPE or PEG-CER with di¡ering acyl chain lengths (C8, C14,
C20, C24). Data represent the mean ( þ S.E.) of three animals.
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lengths of a de¢ned molecular species. No signi¢cant
increases in the plasma concentration of liposomes
24 h after i.v. administration were observed for lip-
osomes containing either C8 or C14 PEG-CER when
compared to SM/chol vesicles without PEG (Fig. 4).
However, the proportions of the injected liposomes
remaining in the circulation after 24 h were signi¢-
cantly increased by the use of the longer-chain C20
and C24 PEG-CER (Fig. 4). Speci¢cally, the plasma
concentrations of lipid were increased by 42% and
66% in the C20 and C24 formulations, respectively,
above those observed for the C8 PEG-CER formu-
lation. The circulation lifetimes achieved with PEG-
DSPE were very similar to those achieved with iden-
tical proportions of the C24 SM/chol/PEG-CER.
A more rigorous pharmacokinetic analysis was
performed on these liposomal vincristine prepara-
tions. The formulation containing the short-chain
C8 PEG-CER underwent a more rapid initial clear-
ance phase followed by a slower clearance rate at
times s 4 h post administration (Fig. 5A). Consis-
tent with the single time-point data presented in
Fig. 4, the clearance kinetics of the C8 PEG-CER
formulation was very similar to the SM/chol formu-
lation without PEG-CER (Fig. 5A). In contrast, the
formulation containing the long-chain C24 PEG-
CER did not have a rapid initial clearance phase,
and the formulation with the intermediate chain
length C20 PEG-CER had clearance kinetics inter-
mediate between the C8 and C24 formulations
(Fig. 5A). The estimated half-lives of the liposomes
in the circulation increased with increases of the acyl
chain length, from 12.7 h and 11.1 h to 14.8 h and
15.2 h for the SM/chol formulations containing C8,
C14, C20 and C24 PEG-CER, respectively.
For these SM/chol liposomes containing vincris-
tine, the presence of the di¡erent chain length
PEG-ceramides had only small e¡ects on the reten-
tion of drug in vivo. In the period between 4 and 24 h
post administration, the leakage of drug was identi-
cal in all formulations. Only the C8 PEG-CER for-
mulation displayed faster vincristine leakage rates in
the period between 1 and 4 h post administration
(data not shown). As a consequence of the liposome
circulation lifetimes and these drug retention charac-
teristics, the vincristine concentrations in the plasma
were very similar in the formulations containing C20
or C24 chain length PEG-CER or lacking PEG-CER
(Fig. 5B). In contrast, SM/chol formulations contain-
ing C8 PEG-CER had signi¢cantly lower plasma
concentrations of vincristine, than observed for car-
riers without PEG-CER or with 5 mol% of either
C20 PEG-CER or C24 PEG-CER (Fig. 5B).
These data indicate that the di¡erent chain length
PEG-CER had di¡erent e¡ects on liposome and drug
pharmacokinetics. For example, the two formula-
tions having rapid and similar lipid clearance from
the circulation (SM/chol and C8 SM/chol/PEG-
CER; Fig. 5A) had the highest (SM/chol) and lowest
(C8 SM/chol/PEG-CER) retention of vincristine in
vivo. In comparison to the long chain length C20
and C24 PEG-CER formulations, the short chain
length C8 PEG-CER had more rapid liposome clear-
ance from the circulation (Fig. 5A) and more rapid
drug leakage (not shown) resulting in the most rapid
Fig. 5. Pharmacokinetic analysis of SM/chol (55:45, mol/mol)
(F) and SM/chol/PEG-CER (50:45:5, mol/mol/mol) formula-
tions of vincristine prepared using ceramide C8 (E), C20 (a),
or C24 (b). (A) Liposomal lipid remaining in the plasma at
various times after i.v. administration. (B) Vincristine remaining
in the plasma at various times after i.v. administration. Data
for SM/chol were recalculated from data presented in Fig. 1.
Data represent the mean ( þ S.E.) of three animals.
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drug clearance from the circulation (Fig. 5B). Over-
all, these data demonstrate the potential of using
PEG-CER having regulated partition rates to
achieve speci¢c liposome and drug pharmacokinetics.
4. Discussion
The anti-tumor activity of vincristine in a variety
of preclinical murine and human xenograft tumor
models is strongly correlated with increased vincris-
tine circulation lifetimes and increased vincristine ac-
cumulation at tumor sites [10]. The dramatic in-
creases in vincristine circulation lifetime and
accumulation at tumor sites achieved through vin-
cristine encapsulation in liposomal carriers [9,11^
14], have been accomplished primarily through in-
creased vincristine retention, rather than increased
circulation longevity of the carrier [7,10]. Unlike
drugs such as doxorubicin which form intraliposomal
crystals [15] and, consequently, have membrane per-
meability properties that are independent of lipid
composition, vincristine is membrane permeable
and its leakage rates can be a¡ected by alterations
in lipid composition [7,9,10]. For this reason, vincris-
tine was chosen to determine the e¡ects of lipid com-
position on the pharmacokinetics, biodistribution
and e⁄cacy of a liposomal anticancer drug. It is
anticipated that the observations reported here will
also apply to other membrane-permeable amphi-
pathic drugs that can be loaded in response to a
transmembrane ion gradient [16]. Similar results to
those presented here have also been observed in
DSPC/cholesterol-based formulations (data not
shown). These well-characterized ‘conventional’ for-
mulations of liposomal vincristine are currently
undergoing phase I and phase II clinical testing [17].
The comparisons between liposomes with di¡erent
PEG-derivatized lipids described here were based on
the previously identi¢ed [7] increases in vincristine
leakage observed for liposomes containing the nega-
tively charged PEG-DSPE (Fig. 1). However, in lip-
osomes containing PEG-DSPE the increased hydro-
dynamic radius arising from the PEG moiety
e¡ectively shields and reduces the negative surface
charge to a modest (near-zero) zeta potential [5].
The low electrophoretic mobility of phosphatidylcho-
line/cholesterol liposomes containing 5 mol% PEG-
DSPE (30.5U1034 cm2/Vs) reported previously [5]
has been con¢rmed in sphingomyelin/cholesterol lip-
osomes in this study (30.83U1034 cm2/Vs; Table 1).
In contrast, the conjugation chemistry employed to
synthesize the PEG-ceramides results in no net
charge (Fig. 1). Therefore, liposomes containing
PEG-CER have no surface charge to shield and
would be expected to have no detectable electropho-
retic mobility (zeta potential or surface charge). This
prediction was con¢rmed in sphingomyelin/cholester-
ol liposomes containing 5 mol% of PEG-ceramide
(Table 1).
Anionic lipids (i.e. phosphatidic acid, phospha-
tidylserine etc.) that confer a negative surface charge
to liposomes [5] also facilitate their rapid removal
from the circulation by mediating an increase in pro-
tein binding to the liposome surface [6]. Consistent
with the observation of low electrophoretic mobilities
in SM/chol liposomes containing either PEG-DSPE
or PEG-CER (Table 1), the study here shows that
these PEG-conjugated lipids conferred very similar
pharmacokinetic properties to SM/chol liposomal
vincristine (Fig. 3) and DSPC/chol liposomal vincris-
tine (data not shown). It should be noted that a near-
zero zeta potential, as assessed by low electrophoretic
mobility, does not solely confer slow elimination of
liposomal systems from the circulation. This is illus-
trated by a comparison of SM/chol and SM/chol/
PEG-DSPE liposomes, both of which have negligible
electrophoretic mobilities (Table 1) but twofold dif-
ferent plasma elimination rates (Fig. 3A). Other fac-
tors associated with the PEG-DSPE and PEG-CER
formulations, such as comparable protein-binding
properties, clearly a¡ect the elimination of these sys-
tems from the circulation.
Liposomes prepared with a positive surface charge
by the incorporation of a cationic lipid (i.e. stearyl-
amine) have signi¢cantly lower permeability to cati-
onic drugs such as verapamil and prochlorperazine
[18] as well as vincristine (Boman and Bally, unpub-
lished data) in comparison to neutral liposomes.
Therefore, it would be predicted that liposomes bear-
ing a negative surface charge would have increased
membrane permeability to vincristine (cationic at in-
traliposomal pH values) by increasing the local vin-
cristine concentration at the bilayer surface, thereby
increasing the transbilayer vincristine concentration
gradient. Consistent with this prediction, the anionic
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lipids DOPS and DSPG signi¢cantly increased the in
vitro leakage of vincristine by 90^253% (Table 1).
Anionic PEG-DSPE added to SM/chol liposomes
also increased the in vivo leakage of vincristine
(Fig. 3B) to an extent intermediate (117%) to that
e¡ected by DOPS and DSPG (Table 1). In contrast,
the neutral PEG-CER was signi¢cantly more e¡ec-
tive than PEG-DSPE at retaining encapsulated drug
and was comparable to neutral SM/chol liposomes
both in vitro (Table 1) and in vivo (Fig. 3B). These
results suggest that the PEG polymer is able to re-
duce interactions with the membrane surface, even
for small molecules that would be expected to readily
gain access to the lipid-water interface.
As part of our e¡orts to develop drug delivery
systems having regulated surface characteristics, we
have investigated the potential for PEG-CER to par-
tition out of liposomes at de¢nable rates. This has
been achieved by using PEG-CER with di¡erent acyl
chain lengths and, consequently, di¡ering propen-
sities to partition from the liposome bilayer to the
surrounding aqueous medium. Quanti¢cation of the
exchange of PEG-CER from liposomal bilayers in
vitro showed di¡erences in the half-lives in the range
between 6 1 min (C8), 8^10 min (C14) and 22 h
(C24) (J. Holland and T.D. Madden, unpublished
data). A quantitative relationship between acyl chain
length and the rate of interbilayer transfer has also
been reported previously for PEG-PE conjugates
[19,20]. The in vivo data presented here are consis-
tent with these in vitro results and indicates that SM/
chol formulations containing PEG-CER with short
acyl chains (C8 and C14) were subject to clearance
identical to that observed for SM/chol liposomes
lacking PEG-CER (Figs. 4 and 5). We interpret these
data to re£ect the rapid exchange of short chain
PEG-CER out of the SM/chol-based liposomes after
i.v. administration and subsequent liposome clear-
ance at rates characteristic of SM/chol liposomes
lacking PEG-lipids. Conversely, SM/chol formula-
tions containing PEG-CER with longer acyl chains
(i.e. C20 and C24) were not subject to rapid removal
in the ¢rst 4 h after i.v. administration (Fig. 5A) and
displayed plasma liposome concentrations approx.
50% higher than those of SM/chol at 24 h after ad-
ministration. (Fig. 4). This indicates that the long
chain PEG-CER remained in the carriers after ad-
ministration and conferred increased circulation life-
times to the liposomes.
A critical element of PEG-lipid conjugates having
regulatable partitioning properties is that they do not
have a deleterious impact on the retention of encap-
sulated drugs. Overall, the only formulation with any
deleterious e¡ects on vincristine encapsulation and
pharmacokinetics was the SM/chol liposome contain-
ing the C8 PEG-CER. For liposomal vincristine, the
presence of most PEG-CER conjugates did not in-
duce drug leakage, in contrast to PEG-DSPE which
increased drug leakage both in vitro (Table 1) and in
vivo (Fig. 3B). Similar studies will have to be per-
formed with other encapsulated therapeutic agents to
determine if this is behavior is representative of other
drug classes.
Taken in sum, these data demonstrate that PEG
conjugated to long chain ceramides is very e¡ective
at increasing the circulation lifetimes of liposomes.
That is, the pharmacokinetics of liposomal carriers
containing PEG-lipids is controlled primarily by the
hydrophilic PEG moiety, rather than by the hydro-
phobic domain, and is una¡ected by the surface
charge conferred by the PEG-to-lipid conjugation
chemistry. In contrast, the PEG-ceramides show sig-
ni¢cantly improved drug retention compared to that
observed in similar formulations containing PEG-
DSPE. Furthermore, the retention of the PEG-cer-
amides in the administered liposomes can be manip-
ulated via alterations in the acyl chain length, facil-
itating the development of regulated release
liposomal formulations of therapeutic agents. Fi-
nally, the major advantage of the neutral PEG-
ceramides arises from the relative independence of
the surface-associated PEG o¡-rates on the surface
charge of the lipid carrier. Delivery systems contain-
ing nucleic acid-based therapeutics, for example, usu-
ally contain cationic lipids to facilitate intracellular
delivery. It would be expected that the partition rates
of PEG-PE derivatives would be markedly sensitive
to the both the cationic lipid content, via electrostatic
attraction, and the lipid acyl chain length via hydro-
phobic interactions. In contrast, the o¡-rates of the
PEG-ceramides would be more readily controlled
simply by the strength of the hydrophobic interac-
tions that can be explicitly regulated via the altera-
tions in acyl chain length.
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